Clover Biopharmaceuticals (HKSE:02197) Debt-to-EBITDA : -0.23 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Clover Biopharmaceuticals Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Clover Biopharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$357.23 Mil. Clover Biopharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$8.59 Mil. Clover Biopharmaceuticals's annualized EBITDA for the quarter that ended in Dec. 2023 was HK$-1,609.33 Mil. Clover Biopharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.23.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Clover Biopharmaceuticals's Debt-to-EBITDA or its related term are showing as below:

HKSE:02197' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -7.42 Med: -0.15 Max: -0.01
Current: -7.42

During the past 5 years, the highest Debt-to-EBITDA Ratio of Clover Biopharmaceuticals was -0.01. The lowest was -7.42. And the median was -0.15.

HKSE:02197's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.31 vs HKSE:02197: -7.42

Clover Biopharmaceuticals Debt-to-EBITDA Historical Data

The historical data trend for Clover Biopharmaceuticals's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clover Biopharmaceuticals Debt-to-EBITDA Chart

Clover Biopharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

-0.35

-0.03

-0.01

-0.15

-7.42

Clover Biopharmaceuticals Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial			-0.01	-0.04	-0.14	0.33	-0.23

Competitive Comparison of Clover Biopharmaceuticals's Debt-to-EBITDA

For the Biotechnology subindustry, Clover Biopharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clover Biopharmaceuticals's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clover Biopharmaceuticals's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Clover Biopharmaceuticals's Debt-to-EBITDA falls into.

Clover Biopharmaceuticals Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Clover Biopharmaceuticals's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(357.226	+	8.589)	/	-49.301
	=	-7.42

Clover Biopharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(357.226	+	8.589)	/	-1609.334
	=	-0.23

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

Clover Biopharmaceuticals (HKSE:02197) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Clover Biopharmaceuticals Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Clover Biopharmaceuticals's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Clover Biopharmaceuticals (HKSE:02197) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clover Biopharmaceuticals Ltd (HKSE:02197) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

1598-1601 West Nanjing Road, 49th Floor, Park Place, Jing’an District, Shanghai, CHN

Website

https://www.cloverbiopharma.com

Clover Biopharmaceuticals Ltd is a clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates for infectious diseases as well as cancer and autoimmune diseases.

Executives

Liang Peng	2101 Beneficial owner
Liang Joshua G	2501 Other
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd.	2102 Investment manager
Aut-xxi Investment Holdings Limited	2201 Interest of corporation controlled by you
Jnry V Holdings Limited	2101 Beneficial owner
Aut-xxi Hk Holdings Limited	2101 Beneficial owner
Aut-xxi Holdings Limited	2201 Interest of corporation controlled by you
Hh Imv Holdings, L.p.	2201 Interest of corporation controlled by you
Hillhouse Fund Iv, L.p.	2201 Interest of corporation controlled by you
Temasek Holdings (private) Limited	2201 Interest of corporation controlled by you
The Core Trust Company Limited	2301 Trustee
Tct (bvi) Limited	2501 Other
Super Novel International Limited	2306 Nominee for another person
Shang Hai Tian He Sheng Tai Qi Ye Guan Li He Huo Qi Ye You Xian He Huo

Clover Biopharmaceuticals (HKSE:02197) Headlines

No Headlines